BIO 2024 Sessions | June 3-6 | San Diego

At BIO 2024, where issues & insights converge, you can access more than 100 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators, and patient advocates committed to ground-breaking therapies and innovation.

Be sure to register for a Premier Access or General Access pass in order to attend these sessions.

Follow this schedule for updates as new speakers and topics become available.

Loading

Partnering with the U.S. Government to Achieve Our National Security Mission
Breakout Session
- Infectious Disease and Vaccines
28ABCDE

APAC: A Top Rate Destination for Complex and Challenging Clinical Trials
Breakout Session
- Asia-Pacific Opportunities
30ABC
Sponsored by:

How to Build a Successful and Competitive Biopharma Ecosystem in Southeast Asia
Breakout Session
- Asia-Pacific Opportunities
30ABC
Mai Zymaris, Counsel - Baker McKenzie

Mr. Phong Tran, CEO - BOUND Therapeutics and siRnaMed Therapeutics

John Mattison, Operating Partner and Chief Medical Information Officer - Arsenal Capital Partners

Anh Hoang-Lindsay, CEO - Jana Care

Alex Wang, Head of Business Development, US & China - Zuellig Pharma

A Discussion on Increasing Healthspan
Breakout Session
- Next Generation Biotherapeutics
23BC
Hilary Brueck, Journalist - Business Insider

Mr. Dan Oliver, CEO & Co-Founder - Rejuvenate Bio

Katharine Grabek, Co-Founder and CSO - Fauna Bio

Jake Becraft, CEO & Founder - Strand Therapeutics

Alex Aravanis, CEO - Moonwalk Biosciences

Jennifer Bergheiser, Chief Business Officer - eGenesis
A Licensing Deal for All Seasons
Breakout Session
- Business Development and Finance
29AB
Jonathan Grinstein, North American Editor - Inside Precision Medicine

Uneek Mehra, CHIEF FINANCIAL & BUSINESS OFFICER - 4DMT

Mr. Kunal Patel, VP of Business Development - Synthekine

Dr. Gavin Samuels, Chief Business Officer - CinRx Pharma

Lesley Stolz, Vice President - Johnson & Johnson Innovation

Richard Wilson, Senior VP, Primary Focus Lead of Genetic Regulation - Astellas Gene Therapies
All Money is NOT Created Equal: The Differences between Angel, Venture and Strategic Capital in the Biotech Funding Ecosystem
Breakout Session
- Business Development and Finance
32AB
Mr. Yaniv Sneor, Founder & Managing Director - Mid Atlantic Bio Angels

Jonathan McClain, Executive Director, Eli Lilly Catalyze team - Eli Lilly

Dr. Max Farina, Senior Associate - 5AM Ventures
Alternative Funding Programs: Protecting Patients in an Ever-Changing Healthcare Landscape
Breakout Session
- Patient Advocacy
26A
Ashira Vantrees, Counsel - Aimed Alliance

Kollet Koulianos, Vice President Payer Relations - National Hemophilia Foundation

Kim Czubaruk, Associate Vice President of Policy - Cancer Care

Richard Meyers, Head, State Policy - Bristol Myers Squibb
Building Capacities in the Industry for Secondary Uses of Health Data: The EHDS Framework
Breakout Session
- AI and Digital Health
24BC
Dr. Montse Daban, Director of Strategic Foresight and International Relations and President - Biocat and The Council of European BioRegions

Dr. Jean Marc Bourez, CEO - EIT Heatlth

Ms. Elina Drakvik, Senior lead, Health Data 2030 - Sitra

Mariano Vázquez, CEO - ELEM Biotech

Aenor Sawyer, Director UC Space Health - University of San Francisco

Brad Ship, Partner - Alira Health
Empowering Real World Patient-Centric Digital Health in Asia with Digital Apps
Breakout Session
- Asia-Pacific Opportunities
30ABC
Dr. Tsu-Hui Liu, Director of Biotechnology, Health, Medicine and Agriculture Division, - Office of Science and Technology Policy, National Science and Technology Council (NSTC)

Dr. Jared Josleyn, Global Head of Digital Healthcare - Sanofi

Mr. Chu-Yie Deng, co-founder and CEO - Health2Sync

Dr. Allen Lien, Chairman & CEO - Acer Medical Inc.
Europe's Policy Environment and the Impact on the Biotech Sector
Breakout Session
- Emerging Opportunities in Global Markets
26B
Justin Pine, Senior Director - Biotechnology Innovation Organization (BIO)

Matias Olsen, Public Affairs & Policy Manager - EUCOPE

Dr. Claire Skentelbery, Director General - EuropaBio

Santoke Naal, Managing Director - IGES UK
Super Session
Fireside Chat with Nauman Shah, Global Head of Business Development, Johnson & Johnson Innovative Medicine
Super Session
- Business Development and Finance
28ABCDE
Sponsored by:

Nauman Shah, Global Head of Business Development - Johnson & Johnson Innovative Medicine
Lessons from the Oregon Trail: Pioneering Gene Therapy in the Real World
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Tom Klima, Chief Operating and Commercial Officer - bluebird bio

Mr. Joe Garrity, Senior Director, Head of Autologous Cell Therapy - Lonza

Tim Olson, Medical Director, Blood and Marrow Transplant Program - Children's Hospital of Philadelphia

Michelle Campbell, Caregiver - N/A

Kirk Davis, Cigna Healthcare Gene Therapy Program, Senior Manager - Cigna
The Cross-Border Applicability of RWD in Decision-Making
Breakout Session
- Regulatory Innovation
31C
Rachel Ehlers, Partner - Baker McKenzie

Michele Colucci, Founder & Managing Partner - DigitalDx Ventures

Michelle Wong, Head of Operations - Octant

Jonathan Fairtlough, Principal - KPMG

Virginia Sanzone, General Counsel - ICU Medical
The Time is Now: Global Perspectives on Preparing for Public Health Emergencies
Breakout Session
- Infectious Disease and Vaccines
29C
Sponsored by:

Brett Sutton, Director, Health & Biosecurity - CSIRO

A New Era for Access and Affordability: Considerations for Patients and Manufacturers in a Post-IRA World
Breakout Session
- Patient Advocacy
26A
Mark Gooding, Managing Director - Avalere

Anna Hyde, Vice President of Advocacy and Access - Arthritis Foundation

Valerie Reynolds, Executive Director - Genentech
A Perspective from the Trenches: Challenges of Budgeting for Gene Therapies, Innovative Payment Systems That Work for Medicaid Departments and Patients, and What the States Need from CMS
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Thomas Barker, Partner - Foley Hoag LLP

Scott McGoohan, Executive Director, Policy and Alliance Development - Vertex Pharmaceuticals

Mr. Jay Newman, SVP, Commercial Development, Pricing & Reimbursement - Spark Therapeutics, Inc.
AI and Regulatory Innovation in Healthcare: Shaping the Future
Breakout Session
- Regulatory Innovation
31C
Paul Howard, Senior Director of Public Policy - Amicus Therapeutics

Lina Nilsson, VP of Product - Recursion

Meredith Brown-Tuttle, Chief Regulatory Strategist - Regulatorium

Shlomo Klapper, COO - Weave
An Insider Look at Top Deals from 2023
Breakout Session
- Business Development and Finance
29AB
Carin Canale-Theakston, CEO - Evoke Canale

Mark McKenna, CEO - Mirador Therapeutics

Enoch Kariuki, President - Endeavor Biomedicines
Biotech Beyond Borders: Emerging Stronger from a Complex Macroenvironment
Breakout Session
- Business Development and Finance
32AB
Mr. Arda Ural, Americas Life Sciences Sector Leader - EY (Ernst & Young)

Mr. Chris Garabedian, VC Portfolio Manager - Perceptive Advisors

Ms. Barbara Ryan, Board Member, Senior Advisor to EY, Indivior, Mink, Invo, SafeCor Pharmaceutical Companies

Brian Bronk, Head of Business Development, Neurology, Rare Diseases, Technology Platforms and R&D Transactions Partnering - Sanofi

Julie Rozenblyum, Senior Vice President, Business Development - BMS
Emerging Technologies Fostering Biotech Innovation Globally
Breakout Session
- Emerging Opportunities in Global Markets
26B
Dr. Falk Ehmann, Head of Innovation and Development Accelerator (IDeA) - European Medicines Agency (EMA)

Dr. Blythe Adamson, Senior Principal Scientist, Head of Outcomes Research - Flatiron Health

Lesley Maloney, Global Regulatory Policy Lead for Digital Health - Genentech, Inc., A Member of the Roche Group

Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission

Robert Schroeder, Head of External Communications - European Innovation Council and SMEs Executive Agency (EISMEA)

Mahesh Yadav, Distinguished Scientist - Genentech
Fireside Chat
Fireside Chat with Nina Kjellson, General Partner, Canaan Partners
Fireside Chat
- Business Development and Finance
30DE
Nina Kjellson, General Partner - Canaan Partners
Fireside Chat
Fireside Chat with Stephen Quake, Head of Science, Chan Zuckerberg Initiative
Fireside Chat
- Next Generation Biotherapeutics
25ABC
Steve Quake, Head of Science - Chan Zuckerberg Initiative
Forging New Pathways to Reimbursement for Digital Therapeutics: Considerations for Payer Coverage
Breakout Session
- AI and Digital Health
24BC
Brigit Kyei-Baffour, Principal - Avalere

Mona Chitre, Pharmacy Officer and President of Pharmacy Solutions - Excellus BlueCross BlueShield

Jon Campbell
Global Policy Perspectives on the Next Generation of Rare Disease Medicines
Breakout Session
- Orphan and Rare Disease
28ABCDE
Sponsored by:

Jannie Oosthuizen, President - Merck

Dr. Karin Hoelzer, Senior Director, Policy and Regulatory Affairs - National Organization for Rare Disorders (NORD)
Let’s Go STEDI: Moving Beyond QALY’s to Understand the True Value of Antimicrobials and Vaccines
Breakout Session
- Infectious Disease and Vaccines
29C
Dr. Ted Buckley, Vice President, Government Affairs - Shionogi

Dr. John Rex, Chief Medical Officer - F2G

Dr. Scott Johnson, CEO/Founder - Medicus Economics

Ms. Ella Balasa, Patient Expert - Balasa Consulting
Longevity Therapeutics Enter Biopharma Mainstream
Breakout Session
- Next Generation Biotherapeutics
23BC
Brian Gormley, Reporter - Wall Street Journal

Dr. Marco Quarta, Founder and CEO - Rubedo Life Sciences

Robert Gould, Operating Partner - Khosla Ventures

Dr. Simone Fantaccini, Chief Scientific Officer & Head of Medical Affairs - Novartis

Cristina Ghenoiu, Investor - Mubadala Capital

Hanadie Yousef, Chief Executive Officer and Co-Founder - Juvena Therapeutics
Patients Wait Less: Streamlining Regulatory Pathways for Cell/Gene Therapies in Asia-Pacific Region
Breakout Session
- Asia-Pacific Opportunities
30ABC
Dr. Pi-Sheng Wang, Deputy Minister - Ministry of Health and Welfare

Akira Sakurai, Deputy Reviewer Director - Pharmaceuticals and Medical Devices Agency

Dr. Yueh-Ping Liu, Director-General - Department of Medical Affairs, Ministry of Health and Welfare

Dr. Maggie Ho, General Manager, Asian Business & CMC Regulatory Development - Amarex Clinical Research, LLC

Joseph Damond, Chair of Health Policy - Edelman Global Advisory

Investissement Québec International

Global Innovation Hub

Agile Biologics Development and Manufacturing Strategies to Meet Market Demand
Breakout Session
- Business Development and Finance
30DE
Sponsored by:
Altering the Regulatory Ecosystem for Pediatric Clinical Programs: Intended and Unintended Consequences
Breakout Session
- Regulatory Innovation
31C
Dr. Catherine Lee, Associate Director, Global Regulatory Policy and Intelligence - Johnson & Johnson

Dr. Laurie Conklin, Senior Director, Pediatric Development - Johnson & Johnson

Dr. Dionna Green, Director, Office of Pediatric Therapeutics - FDA

Dr. Thomas Miller, Global Head, Acute, Chronic & Pediatric Disease Nucleus - Bayer
Avoid the Cycle of “Panic and Neglect": How Ongoing Commitment to Innovative Partnerships Futureproofs Against the Next Pandemic
Breakout Session
- Infectious Disease and Vaccines
29C
Paul Friedrichs, Director - Office of Pandemic Preparedness and Response Policy (OPPR)

Dr. Georges Benjamin, Executive Director - American Public Health Association

Dr. Robert Walker, Senior Vice President and Chief Medical Officer - Novavax, Inc.

Mr. Laurent Muschel, Acting Director General - European Commission, Health Emergency Preparedness and Response Authority (HERA)

Ms. Emma Wheatley, Director, Access and Private Partnerships - CEPI
Creative Structures for Keeping Innovation Alive After the Deal
Breakout Session
- Business Development and Finance
29AB
Mr. Oren Livne, Partner - Baker McKenzie

Gavin Liu, Senior Director, Legal Strategic Transactions - Astellas

Dr. Paul van der Horst, Chief Business Officer - AgomAb Therapeutics

Deepa Talpade, Vice President, Head BD&L and Alliance Mgmt., Oncology - Bayer
Fireside Chat
Fireside Chat with Matt Gline, CEO, Roivant Sciences
Fireside Chat
- Business Development and Finance
25ABC
Michelle Davis, M&A Reporter - Bloomberg News

Matt Gline, Chief Executive Officer - Roivant Sciences
From Patients to Partners: Patient Advocacy and Biotech Collaborate to Accelerate Innovation
Breakout Session
- Patient Advocacy
26A
Anthony Mancini, EVP & Chief Operating Officer - Genmab

Meghan Gutierrez, CEO - Lymphoma Research Foundation

Portia Badham

Dr. Sabine Haubenreisser, Principal Scientific Administrator, Stakeholders and Communications Division - European Medicines Agency (EMA)
Gun Violence Prevention: A Case Study in Passing Meaningful Policies in a Hyper Partisan Era
Special Program
- Regulatory Innovation
28ABCDE
Josh Horwitz, Co-director - Johns Hopkins Center for Gun Violence Solutions

Angus McQuilken, Life Sciences Industry Relationship Executive - McDermott Will & Emery

Jen Pauliukonis, Director of Policy and Programming - Johns Hopkins Center for Gun Violence Solutions

Traci Murphy, Executive Director - Coalition for a Safer Delaware
Innovation Passport: Emerging Opportunities for Company Growth in Global Markets
Breakout Session
- Business Development and Finance
32AB
Ms. Susie Harborth, Chief Business Officer - Breakthrough Properties

Bernard Parker, Chief Business Officer - Shanghai Pharma Biotherapeutics USA, Inc.

Dr. Avi Spier, Executive Director Business Development and Licensing - Novartis

Dr. Kristen Albright, CEO - Prokarium

Wen Qi Ho, Therapeutics Lead - ClavystBio
Investors' Perspectives: Digital Health Trends and Investment Thesis in 2024 and Beyond
Breakout Session
- AI and Digital Health
24BC
Josh Seidenfeld, Partner and Chair, Digital Health - Cooley LLP

Sourav Kole, Managing Director - Dolby Family Ventures

Mara Aspinall, Partner - Illumina Ventures
Quality Standards for Final Preparation of CGT Product at Point of Care (POC)
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Dr. Maria Amaya, Lead External Advocacy, Quality Policy and Advocacy - Genentech, A member of the Roche Group

Dr. Lesbeth Rodriguez, Director, Regulatory Affairs, Policy and Innovation - Bayer

Dr. Maria Sørensen, Specialist, RA CMC Lead - Novo Nordisk

Dr. Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)

Heather Lombardi, Director, Office of Cellular Therapy and Human Tissue - FDA
Unlocking Biotech Growth: Hong Kong as the Gateway to Global Markets
Breakout Session
- Asia-Pacific Opportunities
30ABC
Albert Wong, CEO - Hong Kong Science and Technology Parks Corporation

Andy Wong, Head of Innovation and Technology - Invest Hong Kong

Michael Chen, CEO & Co-founder - Great Bay Bio Limited

Gaobo Zhou, Chief Investment Officer - Simcere Pharmaceutical Group Limited

Vicky Qu, Senior Vice President and Chief of Staff - BioMap
Unlocking Success to Biotech Global Expansion: A Stepwise Game Plan for International Launch
Breakout Session
- Emerging Opportunities in Global Markets
26B
Eduardo Schur, US Health Sciences & Wellness Commercial Strategy and R&D Lead - EY (Ernst & Young)

Tolga Tanguler, CCO - Alnylam Pharmaceuticals

Russell Cox, President & CEO - Epirium Bio

Robert LaCaze, CEO - Mnemo Therapeutics

Ger Brophy, Chair of the Scientific Advisory Board and retiring EVP Biopharma Production - Avantor

Jérôme Revole, Managing Director Healthcare and Lifesciences - Business France North America
Use of AI in mRNA: The New Revolution?
Breakout Session
- Next Generation Biotherapeutics
23BC
Andy French, Director, Data & AI - CGI

Dr. Mathieu Blanchette, Director - McGill University

Christian Barrow, Executive Director - J.P. Morgan

Dr. Petrina Kamya, Vice President and Global Head of AI Platforms, Insilico Medicine - President, Insilico Medicine Canada

Andrew Giessel, Executive Director - Moderna

Ashoka Madduri, Head of Scientific Strategy and CI - mRNA Center of Excellence

Japan - Global Innovation Hub

Global Innovation Hub

Mikiro Suga, Senior Coordinator, Policy Planning Division for Pharmaceutical Industry Promotion and Medical Information Management, Health Policy Bureau - Ministry of Health, Labour and Welfare of Japan (MHLW)

Kozo Saiki, Director General of Japan Machinery Center & Japan External Trade Organization in Brussels/ Special Advisor to METI Minister of Japanese Government in European Affairs

Nobutaka Maekawa, Executive Vice President - Japan External Trade Organization (JETRO)

Overcoming Development, Scale Up and Commercial Production Challenges for Novel Modalities

BioProcess BioProcess Theater

AI's Trial by Fire: Experimental Validation in Drug Discovery
Breakout Session
- AI and Digital Health
24BC
Nitya Sridhar - Power

Dr. Martin Akerman, Co-founder and CTO - Envisagenics

Alex Zhavoronkov, Founder and CEO - InSilico Medicine

Michael Bembem, Director, Data Science and External Innovation - Johnson & Johnson

Etai Jacob, Senior Director, Head of Data Science and AI, Early Oncology - AstraZeneca

Stacie Calad Thomson, Vice Chairperson - Alliance for AI in Healthcare (AAIH)
Avoiding Commercialization Pitfalls for Cell and Gene Therapies
Breakout Session
- Cell and Gene Therapy and Genome Editing
30ABC
Sponsored by:

Lung-I Cheng
Brick-by-Brick: Building a Biotech from Foundation Up with Venture Investor Company Formation
Breakout Session
- Business Development and Finance
26B
Ms. Allison DeAngelis, Reporter - STAT News

Ann Lee-Karlon, Chief Executive Officer and President - EpiBiologics

Dr. Jay Parrish, Chairman and Chief Executive Officer - Pretzel Therapeutics

Mrs. Amy Liu, Investor - Mubadala Capital

Mitchell Mutz, Entrepreneur Partner - Vivo Capital

Sanjay Mistry, Vice President - Johnson & Johnson Innovation
Build Your Product Pipeline with Non-Dilutive Federal Resources
Breakout Session
- Business Development and Finance
29AB
Ms. Stephanie Fertig, Director, NIH Small Business Program - National Institutes of Health (NIH)

Ms. Elaine Haynes, President and CEO - KaloCyte, Inc.

Julius Korley, Associate Vice President, Office of Economic Innovation and Partnerships - University of Delaware

Ms. Meghan Wood, Managing Director - New York Blood Center Ventures
Building a Bioscience Economy Through Supportive State Legislation: A Discussion with State Legislators from California, Massachusetts, and the Midwest
Special Program
- Regulatory Innovation
29C
FDA Townhall

Special Program 25ABC

Dr. Patrizia Cavazzoni, Director, Center for Drug Evaluation and Research - FDA

Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) - U.S. Food and Drug Administration
In and Out of This World: Partnering with Federal Labs
Breakout Session
- Business Development and Finance
32AB
Vladimir Popov, Chief Innovation Officer - Frederick National Laboratory for Cancer Research

Edward Diehl, Commercialization Officer - U.S. Army Medical Research and Development Command

Tara Kirby, Director of the Office of Technology Transfer - National Institute of Health

Dr. Michael Roberts, Chief Scientific Officer - International Space Station National Laboratory

Gillian Fenton, Vaccines Legal Operations - GSK

Dr. Lisa Thomas Read, Vice President, Research and Development - Amivas (US), LLC
Italian Trade Agency

Global Innovation Hub
New Pain Therapeutics: Strategies for Innovation, Investment, and Collaboration
Breakout Session
- Next Generation Biotherapeutics
23BC
Dr. Hernan Bazan, CEO & Co-Founder - South Rampart Pharma, Inc.

Dr. Emily Caporello, Program Director, Division of Translational Research - NINDS, NIH

Paige Cramer Lacatena, Director Business Development and Licensing, HQ Neurology - Merck

Ana Moreno, CEO and Founder - Navega Therapeutics

Dr. Paul Mieyal, Managing Director - Outcome Capital, LLC

Todd Bertoch, Chief Executive Officer at JBR Clinical Research - CenExel
Start-Up Stadium Tuesday Morning

Start-Up Stadium
Strengthening of the Clinical Trials Environment in Europe Under the Accelerating Clinical Trials (ACT EU) Initiative
Breakout Session
- Clinical Trials Innovations
31C
Ms. Laura Pioppo, ACT EU Programme manager - European Medicines Agency (EMA)

Dr. Claire Skentelbery, Director General - EuropaBio

Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission
Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision Neurotherapeutics
Breakout Session
- Brain Health
26A
Alaa Halawa, Executive Director and Head of Healthcare, US Ventures - Mubadala Capital

Carol Suh, Co-founder & Chief Operating Officer - Neumora

Joanne Taylor, Senior Vice President, Research - Gain Therapeutics

Mr. Richard Shea, CEO - Basking Biosciences

Craig Thompson, CEO - Cerevance

ICEX SPAIN TRADE & INVESTMENT

Global Innovation Hub

Polish Investment and Trade Agency

Global Innovation Hub

Swiss Biotech Association

Global Innovation Hub

Hong Kong Science & Technology Parks Corporation

Global Innovation Hub

Super Session
Where to Launch? Expanding Beyond Home and Activating Your Product’s Global Potential
Super Session
- Emerging Opportunities in Global Markets
28ABCDE
Sandra Anderson, Senior Vice President - Cencora

Taiwan BIO

Global Innovation Hub 5A

Student Program: An Introduction to the Biotechnology Industry

Special Program 29AB

Accelerating the Globalization of Cell and Gene Therapies
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Jennifer Rabin, Specialist Leader - Deloitte Consulting LLP

Sumant Ramachandra, CEO - Impact Bio

Dr. Shahrukh Hashmi, Faculty - Mayo Clinic

Kristen Sudol

Fabian Gerlinghaus, CEO - Cellares

Robert Hughes
AI/ML is Transforming R&D and Business
Breakout Session
- AI and Digital Health
24BC
Dr. Maude Tessier, Chief Business Officer - Seismic Therapeutic

Jiye Shi, Vice President - Eli Lilly

Joe McDonald, Chief Data Officer - Odyssey Therapeutics

Karen Akinsanya, President, R&D - Therapeutics - Schrodinger, Inc.

Frank Grams, Chief Commercial Officer - Partex NV
Creative Claiming for Platforms & Products: Designing an IP Strategy to Go Global
Breakout Session
- Intellectual Property
26B
Dr. Tanis Keirstead, Partner - Mewburn Ellis

Ms. Robin Silva, Vice President of Intellectual Property - Xencor, Inc.

Dr. Malathi Lakshmikumaran, Executive Director and Practice Head - Lakshmikumaran & Sridharan

Ms. Yoon Suk SHIN, Senior Partner/Patent Attorney - Lee International IP & Law

Ms. Amy Feng, Managing Partner - Wu, Feng & Zhang
Fireside Chat
Fireside Chat with Robert A. Bradway, Chairman and Chief Executive Officer, Amgen
Fireside Chat
- Business Development and Finance
25ABC
John Crowley, President & CEO - Biotechnology Innovation Organization (BIO)

Robert Bradway, Chief Executive Officer and Chairman - Amgen
Growth Opportunities from Women’s Health Investments
Breakout Session
- Business Development and Finance
30DE
Sheila Mikhail, Board Member, Women's Health Access Matters; Executive Director - BC Ruckus

Ms. Heather Bowerman, CEO & Founder - DotLab

Lucy Pérez, Senior Partner - McKinsey & Company

Stasia Obremskey, Managing Director - RH Capital

Mary Beth Cicero, Co-Founder and CEO - 3Daughters
Joining Forces to Accelerate Innovation in Oncology
Breakout Session
- Oncology
30ABC
Sponsored by:

Visali Ramanathan, Executive Director - Genentech

Gregor Fachinger Fachinger, VP, Head of Oncology & Immuno-Oncology Business Development - Merck KGaA

Susan Graf, Biotech Executive, Board Member & Advisor
NIH Support for Minority Health and Health Disparities Focused on Early-Stage Life Science Companies
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Mr. Michael Banyas, Program Manager - National Institute of Minority and Health Disparities

Dave Whelan, Managing Director - Bespoke Strategies

Dr. Corine Farewell, Director UVM Innovations - University of Vermont

Anna Lisa Somera, CEO - Rhaeos

Ke Zhang, Founder and interim CEO - Allerdia Inc.
Partnering with CROs and their High-Value Network of Providers to Drive Speed, Cost Effectiveness and Quality in your Clinical Development
Breakout Session
- Business Development and Finance
23BC
Sponsored by:

Tom Pike, Chairman and Chief Executive Officer - Foretrea

Jennifer Byrne, Founder and CEO - Javara

Michael Norton, Senior Advisor - Boston Consulting Group

Gadi Saarony, CEO - Advarra
Promising Advances in Neuroscience: New Molecular Targets and Biomarkers
Breakout Session
- Brain Health
26A
Dr. Hank Safferstein, Senior Advisor - UPMC Enterprises

Susanne Ahmari, Assistant Professor, Department of Psychiatry - University of Pittsburgh

Dr. Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience

Dr. Maha Radhakrishnan, Chief Medical Officer - Biogen
Strategies for Antimicrobial Access in LMICs
Breakout Session
- Infectious Disease and Vaccines
29C
Dr. Jomana Musmar, Executive Director of the Presidential Advisory Council for Combating Antibiotic - Resistant Bacteria (PACCARB)

Dr. Monika Schneider, Director, Global AMR Policy - Shionogi

Prof. Kevin Outterson, Executive Director - CARB-X

Mr. Yann Ferrisse, Business Development & Partner Engagement Director - GARDP Foundation
The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
Special Program
- Business Development and Finance
32AB
David Thomas, Senior Vice President, Industry Research - Biotechnology Innovation Organization (BIO)

Start-Up Stadium Tuesday Afternoon

Start-Up Stadium 5B

Breaking the Cycle: Innovations in Addressing Substance Use Disorder
Breakout Session
- Brain Health
26A
Dr. Tam Nguyen, Program Officer - National Institute on Drug Abuse (NIDA)

Dr. Courtney Miller, Founder, Myosin Therapeutics; Professor Department of Molecular Medicine, Department of Neuroscience - UF Scripps Biomedical Research

Joanne Peterson, Founder and Executive Director - Learn to Cope

Dr. James Hickman, Professor of NanoScience, Chemistry, Biomolecular Science, Physics and Electrical Engineering, University of Central Florida; Chief Scientist - Hesperos
Building a More Sustainable Biopharma Innovation Ecosystem
Breakout Session
- Environmental Sustainability
29C
Rachel Kaufman, Head of Global Sustainability - Avantor

Joydeep Ganguly, Senior Vice President of Corporate Operations, and Chief Sustainability Officer - Gilead Sciences

Mark Steen, VP, Sustainability and Climate Initiatives - Corning
Fireside Chat
Fireside Chat with Joshua Boger, PhD, Founder and Former CEO of Vertex Pharmaceuticals; Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed
Fireside Chat
- Business Development and Finance
25ABC
Dr. Joshua Boger, Founder and Former CEO of Vertex Pharmaceuticals - Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed
From Incubation to Acquisition: The Growth Journey of an Early-Stage Company
Breakout Session
- Business Development and Finance
30ABC
Sponsored by:

Melinda Richter, Global Head - Johnson & Johnson

Matt Lorenzi, Vice President - Johnson & Johnson

Colin Farlow, Co-Founder and CEO - Serotiny

Eric Moessinger, Partner - +ND Capital

Leo MacDonald, Vice President - Johnson & Johnson Innovative Medicine
Getting Personal: How the Evolving U.S. Privacy Legal Landscape Impacts Biomedical Research
Breakout Session
- AI and Digital Health
24BC
Justin Pine, Senior Director - Biotechnology Innovation Organization (BIO)

Kimberly Gold, Chief Privacy Officer - Genentech
Microgravity: A Strategic Advantage in R&D
Breakout Session
- Next Generation Biotherapeutics
23BC
Ms. Elizabeth Reynolds, Managing Director - Starburst Aerospace

Kate Rubins, Astronaut - NASA

Mr. Paul Reichert, Associate Principal Scientist - Merck

Rob Garmise, Director of Formulations Development, Exploratory Biopharmaceutics - Bristol Myers Squibb
Optimizing the Investability of Your Lead Program: Data-Driven Approaches for Pipeline Prioritization
Breakout Session
- Business Development and Finance
32AB
Dr. Drew Cutshaw, Senior Associate, Medical Officer - Pappas Capital

Mike Grey, Chairman - Plexium

Ms. Susan Lenderts, Head of Life Sciences - SAS Institute, INC

Ben Davis, Vice President, Corporate Alliances - IQVIA
Preparing for Platforms: Sponsor and Regulator Perspectives on the Platform Technology Designation (PTD)
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Mr. Dylan Bechtle, US Regulatory Policy Lead - Johnson & Johnson

Snehal Naik, Head of Regulatory Policy - Spark Therapeutics

Rob Berlin, Head US Regulatory Policy - GSK

Anne-Virginie Eggimann, Chief Regulatory Officer - Tessera Therapuetics

Antonella Lozito, Executive Director, Regulatory Strategy, Infectious Diseases - Moderna

Dr. Nicole Verdun, Super Office Director, CBER - FDA
Super Session
Superconvergence: How the AI, Genetics, and Biotechnology Revolutions Will Transform our Lives, Work, and World
Super Session
- Next Generation Biotherapeutics
28ABCDE
Jamie Metzl, Founder and Chair - OneShared.World
The Bad and the Ugly: Unpacking Repercussions of the Medicaid Drug Rebate Program Rule
Breakout Session
- Value‚ Patient Access and Reimbursement
29AB
John Murphy, Chief Policy Officer - Biotechnology Innovation Organization (BIO)

Matt Salo, CEO - Salo Health Strategies

Pete Norman, Senior Vice President - Alkermes, Inc.

Ms. Alice Valder Curran, Partner - Hogan Lovells
Workforce, Diversity, Equity, and Inclusion at BIO: Presenting New Survey Data and Exploring Partnerships
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Dr. Ted Love, Chair - BIO Board of Directors

Charlotte Jones-Burton, Founder - Women of Color in Pharma

Mark Royal, Senior Client Partner - Korn Ferry

Jane Barry-Moran, Managing Director, Programs & Research - Out Leadership

Adaptive Reuse: Biomanufacturing Enters A New Age
Breakout Session
- Environmental Sustainability
29C
Matt Gardner, Board Chairman - California Biomanufacturing Center

TJ Silvey, Director - Raymond James

Ella Woger-Nieves, CEO - Invest Puerto Rico

Gordon Zagar, President & Founder - ZCI

Ann-Stewart Patterson, Executive Vice President - CBRE
AI-Generated Invention and the Future of Bio R&D
Breakout Session
- Intellectual Property
26B
Hans Sauer, Deputy General Counsel, VP for IP - Biotechnology Innovation Organization (BIO)

Prof. Ryan Abbott, Partner - Brown, Neri, Smith & Khan, LLP

Mr. Andrei Iancu, Partner - Sullivan & Cromwell LLP

Ms. Sarah Korman, General Counsel - Isomorphic Labs
Becoming an Early Innovation Partner of Choice
Breakout Session
- Business Development and Finance
29AB
David Kane, Managing Partner - Arc Bio Communications

Helena Chaye, CEO - KaliVir

Peter Sandor, Senior Vice President, Primary Focus Lead, Primary Focus Immuno-oncology - Astellas Pharma

Olga Granaturova, CEO - PrivBio

Anna Chen, Principal - Frazier Life Sciences
Best Practices for Managing Your Biotech’s Ca$hflow
Breakout Session
- Business Development and Finance
32AB
Mr. Joel Papernik, Member - Mintz

Ms. Barbara Wood, Executive Vice President, General Counsel and Corporate Secretary - Sellas Life Sciences

Robert Van Nostrand, Board of Directors Member - Intra-Cellular Therapies

Ms. Heidi Henson, Director - Lisata Therapeutics

Mr. Robert Easton - Eastern Strategy, LLC
Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation
Breakout Session
- Brain Health
26A
Ms. Heather McKenzie, Senior Editor - BioSpace

Dr. Laxminarayan Bhat, CEO - Reviva Pharmaceuticals Inc

Dr. Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience

Daniel Karlin, Chief Medical Officer - Mind Medicine (MindMed)

David Benshoof Klein, Co-Founder and CEO - Click Therapeutics
Exploring the Future of Gene Delivery: A Conversation on the Direction for Next-Generation Vectors
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Mr. Ola Tuvesson, Chief Technology Officer - NorthX Biologics

Prof. Johan Rockberg, Professor at the Royal Institute of Technology and Director of GeneNova - Royal Institute of Technology

Dr. Peter de Haan, Founder and Chief Scientific Officer - Amarna Therapeutics BV

Dr. Amy Walker, Vice President of Research and Business Development - 4BaseBio PLC
Exploring the Uncharted: Rare Diseases, Unintended Consequences of the Inflation Reduction Act, and Demonstrating the Value of These Therapies
Breakout Session
- Orphan and Rare Disease
30DE
Sponsored by:

John Murphy, Chief Policy Officer - Biotechnology Innovation Organization (BIO)
Super Session
Fireside Chat with John McDonald, Corporate Vice President, Global Head of Business Development and M&A
Super Session
- Business Development and Finance
28ABCDE
Sponsored by:

John McDonald, Corporate Vice President - Novo Nordisk
Future of Biopharma Innovation: Unleashing the Potential of Emerging Therapeutic Modalities in Oncology and Beyond
Breakout Session
- Next Generation Biotherapeutics
23BC
Romain Bonnot, Principal - ZS Associates

Jesper Haaning, Head of Development External Innovation - Novo Nordisk

Lucas Donigian, Executive Director, Business Development - Zymeworks Inc.

Malik Kaman, Principal - ZS Associates
Highlighting the Power of Patient Organizations: Exploring Initiatives That Drive Equitable Impact for Patients and Communities
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Ms. Deepa Dahal, Co-founder and Partner - DKI Health. LLC

Ms. Mary Stutts, Chief Executive Officer - Healthcare Businesswomen's Association

Mr. Joseph Nadglowski, President and Chief Executive Officer - Obesity Action Coalition

Ms. Christine Verini, CEO - CancerCare

Ms. Sonali Chopra, Executive Director, Patient Advocacy Relations - Genentech a Member of the Roche Group
The Future of Immunology: Path to Precision Medicine
Breakout Session
- Diagnostics and Personalized Medicine
24BC
Sponsored by:

Max Bayer, Staff Reporter - Fierce Biotech

Aileen Lorenzo Pangan, Vice President & Therapeutic Area Head - Merck

Cynthia Bens, Senior Vice President - Personalized Medicine Coalition

Stephan Targan, Director - Cedars-Sinai, Los Angeles

Andres Hurtado-Lorenzo, Senior Vice President - Crohn's and Colitis Foundation

Keynote: Admiral William H. McRaven, U.S. Navy Four-Star Admiral (Retired)

Keynote

John Crowley, President & CEO - Biotechnology Innovation Organization (BIO)

William McRaven, U.S. Navy Four-Star Admiral (Retired)

Incorporating New Technologies in Development and Production, Regulatory Landscapes, and Agile Manufacturing

BioProcess BioProcess Theater

Achieving Commercial Success Through the National Institutes of Health's Intramural Research Program
Breakout Session
- Business Development and Finance
32AB
Dr. Michael Salgaller, Supervisory Specialist, National Cancer Institute Tech Transfer Center - National Institutes of Health (NIH)

Dr. Mark Rohrbaugh, Special Advisor for NIH Technology Transfer - National Institutes of Health (NIH)

Ms. Margaret Anderson, Managing Director - Deloitte Consulting LLP

Dr. Jeffery Alexander, Director, Innovation Policy - RTI International

Melissa Bonner, Chief Scientific Officer - Nvelop Therapeutics
Biotech Partnering in Stormy Seas: Key Insights on Charting a Course to Successful Deal-Making through a Choppy Market
Breakout Session
- Business Development and Finance
29AB
Kate Hillier, Partner - Cooley LLP

Mrs. Barbara Kosacz, COO and General Counsel - Kronos Bio

Brian Cuneo, Senior Partner - ARCH Venture Partners

Mr. Joseph Baroldi, Executive Vice President, Chief Business Officer Ionis Pharmaceuticals - Ionis Pharmaceuticals

Stacy Feld, Regional Head - Johnson & Johnson Innovation
Breaking the Rare Disease Deadlock through Multi-Stakeholder Collaboration
Breakout Session
- Orphan and Rare Disease
26A
Dr. Niklas Blomberg, Executive Director - Innovative Health Initiative

Dr. Annette Bakker, President - Children's Tumor Foundation

Dr. Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute

Dr. Deborah Requesens, Director, JumpStart Program - Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania

Dr. Claire Skentelbery, Director General - EuropaBio
Grassroots Activation Tools You Can Use
Breakout Session
- Patient Advocacy
30DE
Michele Oshman, Vice President, External Affairs - BIO

Sarah Swan, Regional Senior Director, Lead Policy & Government Affairs - Bristol Myers Squibb

Christina Hochul, Head, Strategic Alliance Development - Alexion Pharmaceuticals, Inc
How to De-Risk Drug Development from the Earliest Stages
Breakout Session
- Business Development and Finance
23BC
Sponsored by:

Wyatt Gotbetter, Senior Vice President and Worldwide Head, Access Consulting - PAREXEL

Vivek Mittal, Partner and Managing Director - Health Advances

Abhiram Rao, Director - EQT Life Sciences
Open Innovation in Life Sciences, Decades of Experiences, Time to Regroup!
Breakout Session
- Translational Research
31AB
Junjun Gao, Sr director BD&L - Bayer

Karen Chandross, Head, Strategic Initiatives and Scientific Relations N.A. • R&D North America - Sanofi

Florian Montel, Head of Open Sciences - Boehringher Ingelheim

Pamela Hill, Sr. Director, Head of Open Innovation Program - Astra Zeneca

Vinit Nijhawan, Managing Director - Mass Ventures
Perspectives from Women Powerbrokers
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Mr. Joshua Fox, Member - Mintz

Ms. Anna Turetsky, Principal, Venture Investments - The Mark Foundation for Cancer Research

Laura Indolfi, Chief Executive Officer and Co-Founder - PanTher Therapeutics

Ms. Sabrina Johnson, President and CEO - Daré Bioscience, Inc.
Post-Guidance Opportunities and Challenges with Prescription Drug Use-Related Software (PDURS)
Breakout Session
- AI and Digital Health
24BC
Rob Berlin, Head US Regulatory Policy - GSK

Eva Temkin, Partner - King & Spalding

Renee Beaver, Director, Corporate Counsel - Otsuka America Pharmaceutical, Inc
Rising to the Challenge of Science Regulation: Ensuring Public Policy Keeps Pace with Innovation Ecosystem
Breakout Session
- Environmental Sustainability
29C
Alex Menotti, Vice President, Government Affairs, Policy, and Sustainability - LanzaJet
Start-Up Stadium Wednesday Morning

Start-Up Stadium 5B
Using AI/ML for Identification and Optimization of Therapeutic Molecules
Breakout Session
- AI and Digital Health
30ABC
Sponsored by:

Michal Preminger, Regional Head - Johnson & Johnson Innovation East North America

Justin Scheer, Vice President, Global Head - Johnson & Johnson Innovative Medicine

Joe McDonald, Chief Data Officer - Odyssey Therapeutics

Mark DePristo, CEO and Co-Founder - BigHat Biosciences

Student Program: Entry into Early Careers in Biotechnology

Special Program 29AB

Advancing Innovation: Best Practices for University-Industry Collaboration
Breakout Session
- Translational Research
31AB
Dr. Ed Pagani, Executive Director, Office for External Partnerships, and Assistant VP, External Partnerships - Duke University

Ms. Caroline Lowenthal, Alliance Manager - MIT

Dr. Tari Suprapto, Director, Search & Evaluation (Western US & Canada) - Novo Nordisk

Sunita Rajdev, Director - Licensing and Strategic Alliances, Life Sciences - Stanford University

Doug Krafte, Site Head – Durham, North Carolina, and Sr. Vice President, Ion Channels/Transporters - OmniAb
Applied AI & Advanced Automation in Clinical Development
Breakout Session
- AI and Digital Health
30ABC
Sponsored by:

Bryan Katz, Chief Strategy Officer - ProPharma
Biotech Innovations for Pet Health
Breakout Session
- Environmental Sustainability
29C
Ellen Carlin, Vice President - Pathway Policy Group

Tammie Wahaus, CEO - Elias Animal Health LLC

Dylan Balsz, CEO - Anivive Lifesciences

Dr. Megan Grether, Global Head of Business Development & Licensing, Animal Health - Boehringer Ingelheim Animal Health
Building Winning Presentations and Using Emotional Intelligence as a Tool for Success
Breakout Session
- Business Development and Finance
32AB
Mrs. Elise Simard, Speaker Trainer/Coach - LaVoieHealthScience

Mrs. Donna LaVoie, Founder & CEO - LaVoieHealthScience
Cell Therapy Primer
Breakout Session
- Cell and Gene Therapy and Genome Editing
23BC
Dr. Kevin Curran, Scientific Advisor and Instructor - BioTech Primer
Changing Clinical Trial Designs in the IRA Environment and Impacts on Stakeholders in Rare and Ultra-Rare Disease Space
Breakout Session
- Orphan and Rare Disease
26A
Ms. Mariia Salova, Senior Consultant - Avalere

Amy House, Head of Portfolio Strategy - Beacon Therapeutics

Primal Kaur, Vice President, Global Development - Amgen

Matthew Klein, Chief Executive Officer and President - PTC Therapeutics

Mike Stodghill, Patient Perspective - Mackenzie's Mission
Diversifying the Talent Pipeline: Industry-Recognized Curriculum for a Skilled Workforce
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Ms. Vicki Brannock, Senior Director Workforce Strategy & Innovation - Biocom California Institute

Mr. Scott Eaker, Chief Operations Officer - Prolacta

Mr. Willie Zuniga, Retired, Former President and Site Head - Grifols Biologicals

Mrs. Judith Velasco, Executive Director - Verdugo Workforce Development Board

Dr. Linnea Fletcher, Executive Director - InnovATEBIO, National Biotechnology Center
New Tools, New Times: Chemical and Structural AI for Drug Discovery
Breakout Session
- AI and Digital Health
24BC
Mr. Ayman AlAbdallah, Partner - Mubadala Capital

Prof Lee Cronin, Founder and Chief Executive Officer - Chemify

Mr. Raphael Townshend, Founder & CEO - Atomic AI

Tom Miller, CEO and co-founder - Iambic Therapeutics
Pioneering Paths: Navigating the Frontiers of First-in-Class

Breakout Session 30DE

Sponsored by:

Seth Ettenberg, President and CEO - BlueRock Therapeutics

John Wu, Managing Direct and Partner - Boston Consulting Group

Hanadie Yousef, Chief Executive Officer and Co-Founder - Juvena Therapeutics
The Oncology Endgame: Assemble and Shine with AI and Precision Medicine, or Lose.
Breakout Session
- Oncology
26B
Dr. Karim Budhwani, CEO-Scientist - CerFlux

Tahera Kan, Vice President, Head of Precision Medicine - Johnson & Johnson

Dr. Sandeep Menon, Chief Scientific Officer, AI Digital Sciences and SVP, Head of Early Clinical Development - Pfizer

Dr. Maggie Scully, Partnership Development Director - Frederick National Laboratory for Cancer Research

Start-Up Stadium Wednesday Afternoon

Start-Up Stadium 5B

Adult Vaccination: New Vaccines, New Opportunities to Protect Public Health
Breakout Session
- Infectious Disease and Vaccines
32AB
Sponsored by:

Jannie Oosthuizen, President - Merck

Abby Bownas, Manager - Adult Vaccine Access Coalition
Biotech as Climate Tech: Sustainable Production in Pharma, Ag, and Industry

Breakout Session 29C
Co-opting Biological Processes to Drug Cancer and Other Diseases
Breakout Session
- Oncology
26B
Mariana Mihalusova, Investor - Venrock

Dr. Larry Hamann, Co-founder/CEO - Interdict Bio

Aetna Wun Trombley, CEO - Lycia

Mr. Bernd Boidol, CEO - Proxygen

Dr. Brian Fiske, Co-founder/CSO - Mythic Therapeutics
Enhancing Clinical Trial Diversity Through a Patient-Centric, Data Driven Approach
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Elena Martinez, Professor, Herbert Wertheim School of Public Health and Human Longevity Science; Associate Director of Population Sciences - UC San Diego Moores Cancer Center

Dr. Trevan Locke, Assistant Research Director - Duke-Margolis Institute for Health Policy

Megan Fesinmeyer, Observational Research Senior Manager - Amgen

Carla Rodriguez-Watson, Director of Research

Darryl Sleep, Head, Global Public Health - Amgen
Evolution of the IRA: A New-Year, a Potential New Administration, Yet Tackling the Same Access and Affordability Challenges
Breakout Session
- Value‚ Patient Access and Reimbursement
23BC
Mr. Stephen Morales, Senior Principal - Blue Fin Group, An IntegriChain Company

Gerry Gleeson, Head of US Market Access - Sanofi

Bill Sarraille, Retired Senior Partner - Sidley Austin LLC

Albert Thigpen, Operating Advisor - Nautic Partners

Bill Roth, Founding Partner - Blue Fin Group
IPOs Are Starting to Come Back: Are You Ready?
Breakout Session
- Business Development and Finance
29AB
Mr. Rich Ramko, Partner, US Biotech Leader - EY (Ernst & Young)

Steven Spector, Executive Vice President, Head of Business Development and General Counsel - Longboard Pharma

Brad Wolff, Senior Managing Director |Global Advisory | Strategic Advisory | Mergers and Acquisition - Evercore

Arvind Kush, CFO - RayzeBio

Kristin VanderPas, Partner - Cooley
Moving from the Lab Bench to the Biotech C-Suite: Insights on Running a Founder-Led Biotech
Breakout Session
- Translational Research
31AB
Max Bayer, Staff Reporter - Fierce Biotech

Kevin Parker, CEO and Co-founder - Cartography Biosciences

Mr. Jordi Mata-Fink, CEO and Co-founder - Gate Bioscience

Mr. Trevor Martin, CEO and Co-founder - Mammoth Biosciences

Dr. Kira Poskanzer, Founder-in-Residence - Arcadia Science

Ms. Heather Bowerman, CEO & Founder - DotLab
Overcoming Systemic Data Bias via AI and Digital Health Tools: Perspectives from Providers, Pharma and Innovators
Breakout Session
- AI and Digital Health
24BC
Alexis Bortniker, Partner - Cooley LLP

Kal Patel, CEO - Brightsight
Policy and Practice Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Precision Oncology
Breakout Session
- Diagnostics and Personalized Medicine
26A
Dr. Daryl Pritchard, Senior Vice President - Personalized Medicine Coalition

Jonathan Katchmore, Vice President of Commercial Diagnostic Strategy - Eli Lilly

Dr. Peter Hulick, Medical Director, Center for Personalized Medicine - NorthShore / Endeavor Health

Mr. Robert Dumanois, Director, Reimbursement Strategy - Thermo Fisher Scientific

Wendy Levin, Chief Medical Officer - Biofidelity

Start-Up Stadium Thursday

Start-Up Stadium 5B

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

Loading